Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Österlund Pia) > Intravenous versus ...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		04800naa a2200529 4500
001		oai:DiVA.org:uu-351690
003		SwePub
008		180604s2018 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3516902 URI
024	7	a https://doi.org/10.1007/s12032-018-1103-x2 DOI
040		a (SwePub)uu
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Ali, Abir Salwau Uppsala universitet,Onkologisk endokrinologi4 aut0 (Swepub:uu)abali010
245	1 0	a Intravenous versus oral etoposide :b efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
264		c 2018-03-06
264	1	b Springer,c 2018
338		a electronic2 rdacarrier
520		a High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs, G3) are aggressive cancers of the digestive system with poor prognosis and survival. Platinum-based chemotherapy (cisplatin/carboplatin + etoposide) is considered the first-line palliative treatment. Etoposide is frequently administered intravenously; however, oral etoposide may be used as an alternative. Concerns for oral etoposide include decreased bioavailability, inter-and intra-patient variability and patient compliance. We aimed to evaluate possible differences in progression-free survival (PFS) and overall survival (OS) in patients treated with oral etoposide compared to etoposide given as infusion. Patients (n = 236) from the Nordic NEC study were divided into three groups receiving etoposide as a long infusion (24 h, n = 170), short infusion (= 5 h, n = 33) or oral etoposide (n = 33) according to hospital tradition. PFS and OS were analyzed with Kaplan-Meier (log-rank), cox proportional hazard ratios and confidence intervals. No statistical differences were observed in PFS or OS when comparing patients receiving long infusion (median PFS 3.8 months, median OS 14.5 months), short infusion (PFS 5.6 months, OS 11.0 months) or oral etoposide (PFS 5.4 months, OS 11.3 months). We observed equal efficacy for the three administration routes suggesting oral etoposide may be safe and efficient in treating high-grade GEP-NEN, G3 patients scheduled for cisplatin/carboplatin + etoposide therapy.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653		a Chemotherapy
653		a Intravenous
653		a Oral
653		a Etoposide
653		a Neuroendocrine neoplasms
653		a WHO G3
700	1	a Grönberg, Malin,d 1980-u Uppsala universitet,Onkologisk endokrinologi4 aut0 (Swepub:uu)magro676
700	1	a Langer, Seppo W.u Univ Copenhagen, Rigshosp, Fac Hlth Sci, Dept Surg C, Copenhagen, Denmark.;Univ Copenhagen, Rigshosp, Fac Hlth Sci, Dept Endocrinol PE, Copenhagen, Denmark.;Rigshosp, Copenhagen Univ Hosp, Dept Oncol, Copenhagen, Denmark.4 aut
700	1	a Ladekarl, Mortenu Aarhus Univ Hosp, Dept Oncol, Aarhus, Denmark.4 aut
700	1	a Hjortland, Geir Olavu Oslo Univ Hosp, Dept Oncol, Oslo, Norway.4 aut
700	1	a Vestermark, Lene Weberu Odense Univ Hosp, Dept Oncol, Odense, Denmark.4 aut
700	1	a Österlund, Piau Tampere Univ Hosp, Dept Oncol, Tampere, Finland.;Tampere Univ, Tampere, Finland.;Helsinki Univ Hosp, Dept Oncol, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.4 aut
700	1	a Welin, Staffanu Uppsala universitet,Onkologisk endokrinologi4 aut0 (Swepub:uu)stafweli
700	1	a Gronbaek, Henningu Aarhus Univ Hosp, Dept Hepatol, Aarhus, Denmark.;Aarhus Univ Hosp, Dept Gastroenterol, Aarhus, Denmark.4 aut
700	1	a Knigge, Ulrichu Univ Copenhagen, Rigshosp, Fac Hlth Sci, Dept Surg C, Copenhagen, Denmark.;Univ Copenhagen, Rigshosp, Fac Hlth Sci, Dept Endocrinol PE, Copenhagen, Denmark.;Rigshosp, Copenhagen Univ Hosp, Dept Oncol, Copenhagen, Denmark.4 aut
700	1	a Sorbye, Halfdanu Haukeland Hosp, Dept Oncol, Bergen, Norway.4 aut
700	1	a Janson, Eva Tiensuuu Uppsala universitet,Onkologisk endokrinologi4 aut0 (Swepub:uu)evatieja
710	2	a Uppsala universitetb Onkologisk endokrinologi4 org
773	0	t Medical Oncologyd : Springerg 35:4q 35:4x 1357-0560x 1559-131X
856	4	u https://doi.org/10.1007/s12032-018-1103-xy Fulltext
856	4	u https://uu.diva-portal.org/smash/get/diva2:1213133/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
856	4	u https://link.springer.com/content/pdf/10.1007%2Fs12032-018-1103-x.pdf
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-351690
856	4 8	u https://doi.org/10.1007/s12032-018-1103-x

Hitta via bibliotek

Medical Oncology (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Ali, Abir Salwa; Grönberg, Malin, ...; Langer, Seppo W.; Ladekarl, Morten; Hjortland, Geir ...; Vestermark, Lene ...; visa fler...; Österlund, Pia; Welin, Staffan; Gronbaek, Hennin ...; Knigge, Ulrich; Sorbye, Halfdan; Janson, Eva Tien ...; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Artiklar i publikationen: Medical Oncology

Av lärosätet: Uppsala universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se